GlassScriptPhysician profile
Pankhuri Gupta
NPI 1598107187
$58,121.51
in general payments reported to CMS, 2019-2025
20 companies · $49K in 2025
The $49K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $298 · 2021: $341 · 2022: $845 · 2023: $389 · 2024: $6,999 · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Travel and Lodging: $4,999 · Consulting Fee: $4,165 · Food and Beverage: $3,168 · Honoraria: $200 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,330.00 |
| Travel and Lodging | $4,999.01 |
| Consulting Fee | $4,165.00 |
| Food and Beverage | $3,168.07 |
| Honoraria | $200.00 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23,276.49 | 2022-2025 | Saphnelo |
| Amgen INC. | $20,438.58 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| Glaxosmithkline, LLC. | $9,839.33 | 2019-2025 | Benlysta, Nucala |
| Ucb, INC. | $2,064.85 | 2022-2025 | Bimzelx |
| Horizon Therapeutics Plc | $721.90 | 2019-2023 | Krystexxa |
| Abbvie INC. | $581.37 | 2019-2025 | |
| Janssen Biotech, INC. | $377.00 | 2019-2024 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $222.83 | 2019-2024 | |
| Pfizer INC. | $149.86 | 2020-2024 | |
| Lilly USA, LLC | $110.68 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $59.85 | 2024 | Orencia |
| Genentech USA, INC. | $59.16 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $56.84 | 2022 | |
| Genzyme Corporation | $42.42 | 2025 | |
| Boston Scientific Corporation | $34.34 | 2025 | Watchman Flx |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $21.18 | 2022 | |
| Radius Health, INC. | $18.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.98 | 2020 | |
| Celgene Corporation | $16.32 | 2019 | |
| Merck Sharp & Dohme LLC | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pankhuri Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.